Ahmet Baran

Ahmet Baran

Auto-generated profile, based on publicly available information

Ahmet Baran

Samsun Eğitim ve Araştırma Hastanesi

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2023 in Kastamonu Medical Journal
Verified
Journal Article
Open access
PDF file
ESEla Delikgöz Soykut
Ela Delikgöz Soykut
NSNilgun Sahin
Nilgun Sahin
EOEylem Odabasi
Eylem Odabasi
DADonay Aksan
Donay Aksan
ABAhmet Baran
Ahmet Baran
HTHatice Tataroglu
Hatice Tataroglu
Aims: The incidence of brain metastases in patients with renal cell carcinoma (RCC) and malignant melanoma (MM) with radioresistant histologies is over 50%. Stereotactic radiodiosurgery (SRS) may be beneficial in treating radioresistant histologies. The effectiveness of SRS in terms of local control and survival rates in the treatment of patients with radioresistant brain metastases was the focus of our study. Methods: A retrospective review of RCC and MM brain metastases treated with SRS between 2013 and 2020 was conducted. Local control rates, distant brain metastases free survival, and overall survival (OS) were study endpoints. Results: 55 brain metastases were detected in 29 patients, 14 of whom were MM and 15 were RCC. The median follow-up time was 13 (1-89) months. The 1-y and 3-y actuarial local control rates were 82.4% and 59%, respectively. Increased size and volume of brain metastases were associated with progressive disease (p=0.041, p=0.002). Local control rates were increased in those receiving whole brain radiotherapy (WBRT) prior to SRS (0.008). The 1-y and 3-y distant brain metastases free survival were 87.7% and 60.2%, respectively, and increased in those receiving WBRT before SRS, but not statistically significant (p=0.403). The median OS was 8 months (HR: 1.79, 95% CI: 4.48-11.51). There was no difference in OS according to whether the primary disease diagnosis was RCC or MM (p=0.482). Patients with 1-2 brain metastases had better OS than patients with 3 or more brain metastases (p=0.029). Recursive partitioning analysis (RPA) and graded prognostic assessment (GPA) prognostic risk scores were significantly related to OS (p=0.001, p<0.001). OS worsened in patients who received WBRT before SRS compared to those who did not (0.035). OS increased statistically in patients who received immunotherapy (p=0.033). Conclusion: Improvement in local control was found in patients with small tumor diameter and volume. The addition of WBRT to the SRS increased both local control and distant brain metastasis free survival. Regarding OS, multiple metastases, high RPA score, and low GPA score worsened OS. Another crucial observation is that a positive predictive effect on OS was detected in patients in whom immunotherapy was combined with SRS.

1 January 2023 in Journal of Contemporary Medicine
Verified
Journal Article
Open access
PDF file
ESEla Deli̇kgöz Soykut
Ela Deli̇kgöz Soykut
EOEylem Odabasi̇
Eylem Odabasi̇
SŞSerdar Şenol
Serdar Şenol
SYSalih Buğra YILMAZ
Salih Buğra YILMAZ
HTHatice Tataroğlu
Hatice Tataroğlu
ABAhmet Baran
Ahmet Baran
Aim: Gastrointestinal cancers rarely metastasize to the brain and constitute 4-8% of all brain metastases (BM). Survival is generally poor for BM from gastrointestinal cancers and stereotactic radiosurgery (SRS) is frequently used in its management. Since the data are still insufficient due to their rare presentation, we aim to analyze the clinical results of patients who underwent SRS for BM due to gastrointestinal cancers. Material and Method: We retrospectively reviewed patients with BM from gastrointestinal cancers who received robotic SRS with CyberKnife at our institute from October 2013 to December 2022. Clinical characteristics and treatment outcomes were recorded. Study endpoints were local control rates, distant brain control rates, and overall survival (OS). Results: A total of 61 BM were detected in 42 patients. The median clinical follow-up time was 7 (0.5-36) months. Nine lesions progressed in the irradiated area, 14 new lesions were observed outside the irradiated area. The local control rate was 85.1% and the distant brain control rate was 77%. The median OS was 8 months; 12-month and 24-month OS were 31.6% and 10.5%, respectively. Patients with high performance status had better OS (p=0.016). The prognostic scoring scales RPA and GI-GPA were both associated with OS (p=0.049, p=0.002). Multivariate analysis found a significant association between GI-GPA classes and OS (p=0.011). Conclusion: We obtained comparable results in terms of local control, distant brain control and OS in this challenging patient population. The use of GI-GPA prognostic scoring scales in routine practice will guide the selection of the most appropriate patient for SRS.

30 August 2023 in Journal of Medicine and Palliative Care
Verified
Journal Article
Open access
PDF file
ESEla Deli̇kgöz Soykut
Ela Deli̇kgöz Soykut
EOEylem Odabasi̇
Eylem Odabasi̇
NŞNilgün Şahi̇n
Nilgün Şahi̇n
ABAhmet Baran
Ahmet Baran
HTHAKAN TABAN
HAKAN TABAN
AÜAsude Ünal
Asude Ünal
Aims: Organ-preserving approach is recommended as an evidence-based treatment option for advanced laryngeal cancer (LC) with similar survival results. However, the organ-preserving approach in T4 disease is controversial, and surgical treatment is primarily preferred. Today, chemoradiotherapy (CRT) is applied to T4 LC patients who are inoperable for medical or surgical reasons and upon the request of the patient who refuses the recommended surgical treatment. The aim of this study was to evaluate the treatment outcomes in patients with T4 LC who underwent CRT for these conditions and received adjuvant radiotherapy (RT)/CRT as the standard treatment regimen after surgery. Methods: A retrospective review of T4 LC patients treated with CRT (17 patients) and adjuvant RT/CRT (26 patients) between 2015 and 2021 was conducted. Overall survival (OS), local regional recurrence-free survival (LRRFS), and disease-free survival (DFS) were compared between the groups. The organ preservation rate was determined for the CRT group. Results: The median follow-up time for the entire cohort was 41 months, the 5-y OS, LRRFS, and DFS were 55.9%, 51.4%, and 51.9%, respectively. Statistically significant difference was found between the treatment groups in terms of 5-y OS, LRRFS, and DFS rates, and survival was found to be decreased in the CRT group (35.3% vs. 70.2%, p=0.007; 22.1% vs. 75.1%, p= 0.001; 22.1% vs. 75.7%, p=0.001). With respect to other clinicopathological factors, age was the only significant factor in on OS in multivariate analysis, whereas tumor size, nodal stage, and ECE (in the postoperative RT group, except LRRFS) were linked with OS, LRRFS, and DFS rates. Among the patients who underwent CRT, OS was found to be better in the group applied due to the patient’s request compared to the patients referred for RT due to medical or surgical inoperability, and in multivariate analysis, the indication for RT remained an independent predictor of OS. In addition, the 3-y organ preservation rate was 81.5% in the CRT group. Conclusion: The surgical arm had statistically significantly superior results in terms of OS, LRRFS, DFS compared to the CRT group. However, it is also noteworthy that OS was better in cases where RT is applied at the patient’s request without inoperable disease. In addition, laryngeal protection was observed to a large extent in the CRT arm.